Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745736 | 0.85 | EPHX1 (0.38) | EPHX1ADRB2HTR1ASLC6A2HTR2A | |
| SCHEMBL23745351 | 0.82 | SLC6A2 (0.41) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL8657970 | 0.78 | EPHX1 (0.60) | EPHX1ADRB2HTR1ASLC6A2HTR2A | |
| SCHEMBL17649948 | 0.78 | EPHX1 (0.60) | EPHX1ADRB2HTR1ASLC6A2HTR2A | |
| SCHEMBL16652362 | 0.78 | EPHX1 (0.60) | EPHX1ADRB2HTR1ASLC6A2HTR2A | |
| SCHEMBL16652905 | 0.78 | EPHX1 (0.60) | EPHX1ADRB2HTR1ASLC6A2HTR2A | |
| SCHEMBL4423889 | 0.78 | EPHX1 (0.60) | EPHX1ADRB2HTR1ASLC6A2HTR2A | |
| SCHEMBL4426423 | 0.78 | EPHX1 (0.60) | EPHX1ADRB2HTR1ASLC6A2HTR2A | |
| SCHEMBL8661751 | 0.78 | EPHX1 (0.60) | EPHX1ADRB2HTR1ASLC6A2HTR2A | |
| SCHEMBL5712866 | 0.78 | EPHX1 (0.60) | EPHX1ADRB2HTR1ASLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | EPHX1 520/4885ADRB2 4261/4885HTR1A 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.